Press releases
- Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test
- Agilent Included in Just Capital’s 2023 List of Most Just Companies
- Agilent Authorizes $2 Billion Share Repurchase Program
- Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics
- Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
- Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research
- Agilent to Present at Goldman Sachs and J.P. Morgan Healthcare Conferences
- Agilent Resolution ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer
- Agilent Again Named to Newsweek’s List of America’s Most Responsible Companies
- Agilent Opens Customer Experience Center Highlighting Genomics and Diagnostics Solutions
More ▼
Key statistics
As of last trade AGILENT TECHDRN (A1GI34:SAO) traded at 397.75, -2.60% below its 52-week high of 408.36, set on Jan 23, 2023.
52-week range
Markit short selling activity
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | 389.11 |
Offer | 390.20 |
Previous close | 397.75 |
Average volume | 1.00 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Annual div (ADY) | 1.54 BRL |
---|---|
Annual div yield (ADY) | 0.39% |
Div ex-date | Jan 02 2023 |
Div pay-date | Jan 31 2023 |
Data delayed at least 15 minutes, as of Jan 27 2023.
More ▼